Emduo-n 30/40 Tablets

Each Emduo-N 30/40 Tablets contains:
Stavudine IP - 30/40 mg
Lamivudine IP - 150 mg

Each uncoated tablet contains:
Nevirapine IP - 200 mg

Indication:
In the initial management of Human Immunodeficiency Virus (HIV) infection

Contraindication:
Patients with hypersensitivity to any of the components of the formulation.

Warnings and precautions:
Lamivudine, Stavudine and Nevirapine should be used with caution in patients with hepatic disease or in those with known risk factors for liver disease. Lamivudine should be used with caution in patients with impaired renal function, including renal failure. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including Lamivudine, Stavudine alone or in combination with other antiretrovirals. Treatment should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity. Motor weakness, Peripheral neuropathy, and pancreatitis may occur with Stavudine. Severe or life-threatening hepatotoxicity, including fatal fulminant hepatitis has occurred in patients treated with Nevirapine. Severe life-threatening skin reactions have occurred in patients receiving Nevirapine. Treatment with Nevirapine should be withheld in patients with moderate or severe AST and ALT abnormalities. Nevirapine should be discontinued in patients developing signs or symptoms of severe skin reactions.